Peter Lawson
Stock Analyst at Barclays
(2.07)
# 2,945
Out of 5,172 analysts
102
Total ratings
41.57%
Success rate
-7.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Overweight | $394 → $405 | $275.28 | +47.12% | 3 | Feb 27, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $24.23 | -9.20% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $90.78 | +11.26% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $32.75 | +22.14% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $12.02 | +107.99% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $6.98 | -57.02% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $41.27 | -3.08% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $2.86 | +4.90% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.10 | +81.82% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $7.63 | +31.06% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $3.69 | +8.40% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $12.13 | -50.54% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $52 | $29.91 | +73.85% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $8.26 | +33.17% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $10.94 | +46.25% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $4.35 | +244.83% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $21.64 | -35.30% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.14 | +163.16% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.04 | +188.46% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.46 | +173.97% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $95.78 | -37.36% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $9.91 | +71.54% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $14.43 | +114.83% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $19.42 | -33.06% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $2.99 | +67.22% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $4.45 | -21.35% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $124.33 | +193.57% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $27.86 | +65.11% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $72.22 | +523.10% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.34 | +1,823.08% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $46.24 | -2.68% | 2 | Jan 23, 2018 |
BeOne Medicines AG
Feb 27, 2026
Maintains: Overweight
Price Target: $394 → $405
Current: $275.28
Upside: +47.12%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $24.23
Upside: -9.20%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $90.78
Upside: +11.26%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $32.75
Upside: +22.14%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $12.02
Upside: +107.99%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $6.98
Upside: -57.02%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $41.27
Upside: -3.08%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $2.86
Upside: +4.90%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.10
Upside: +81.82%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $7.63
Upside: +31.06%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.69
Upside: +8.40%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $12.13
Upside: -50.54%
May 7, 2025
Maintains: Overweight
Price Target: $66 → $52
Current: $29.91
Upside: +73.85%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $8.26
Upside: +33.17%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $10.94
Upside: +46.25%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $4.35
Upside: +244.83%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $21.64
Upside: -35.30%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.14
Upside: +163.16%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.04
Upside: +188.46%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.46
Upside: +173.97%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $95.78
Upside: -37.36%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $9.91
Upside: +71.54%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $14.43
Upside: +114.83%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $19.42
Upside: -33.06%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.99
Upside: +67.22%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $4.45
Upside: -21.35%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $124.33
Upside: +193.57%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $27.86
Upside: +65.11%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $72.22
Upside: +523.10%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.34
Upside: +1,823.08%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $46.24
Upside: -2.68%